U.S. Foundation Opportunities in Sustainable Fiber and Textiles

July 12, 2017

Over the past four decades, a movement to re-examine, re-localize, and improve the sustainability of food production and processing has grown dramatically in the U.S. and globally. U.S. nonprofits have played a key role in raising public awareness and creating alternatives to entrenched systems of food production and distribution, and U.S. foundations have spurred this movement through significant funding investments.

Spotlight

Trevena, Inc.

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target G protein coupled receptors, or GPCRs. We are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. We have identified four biased ligand drug candidates: TRV130, an FDA-designated Breakthrough Therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; TRV027 was evaluated in a Phase 2b study for the treatment.

OTHER WHITEPAPERS
news image

Employee Scheduling for Manufacturing: A Best Practices Guide

whitePaper | June 16, 2021

As demand continues to surge for many chemical manufacturers, ensuring adequate staffing to meet daily volume targets is a top-of-mind issue for plant managers. Read the guide to discover the best practices of employee scheduling you can leverage to improve the overall effectiveness of labor resources

Read More
news image

Empower the Intelligent Chemical Enterprisewith SAP and its Ecosystem

whitePaper | December 27, 2019

The chemical industry has its roots in selling products made from crude oil and inorganics into a variety of downstream industries such as consumer products or life sciences, pharmaceuticals, automotive and hitech, just to name a few. Finding new molecular structures, scaling them up and selling them in a B2B fashion.

Read More
news image

THE INTELLIGENT ENTERPRISE FOR THE CHEMICAL INDUSTRY

whitePaper | April 7, 2022

Mastering future challenges and delivering new customer experiences through innovative products, services, and business models

Read More
news image

2023 Long-Term Capital Market Assumptions

whitePaper | January 2, 2023

By nearly any measure, the early 2020s have been a period of extraordinary challenge. The worst pandemic in over a century triggered a short but severe recession and enduring supply disruptions. A generous fiscal response, facilitated by unusually easy monetary policy, fueled the highest levels of inflation since the early 1980s

Read More
news image

Investor Update October 2022

whitePaper | October 11, 2022

Completed to acquire additional stakes in Lotus Pharmaceutical to be 37% and invest in Adalvo 60%. Profit contribution started in 2Q22

Read More
news image

Liability and Coverage for the “Forever Chemicals”

whitePaper | May 11, 2022

For decades, BatesCarey has litigated insurance coverage disputes involving nationwide environmental pollution claims arising from an ever-evolving recognition of the toxicity of<br /> everyday products once thought to be innocuous, or even beneficial to society.

Read More

Spotlight

Trevena, Inc.

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target G protein coupled receptors, or GPCRs. We are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. We have identified four biased ligand drug candidates: TRV130, an FDA-designated Breakthrough Therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; TRV027 was evaluated in a Phase 2b study for the treatment.

Events